Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules

Nature Biotechnology

Volumn 17, Issue 6, 1999, Pages 562-567

  Falcioni, Fiorenza ^a   Ito, Kouichi ^a   Vidovic, Damir ^a   Belunis, Charles ^a   Campbell, Robert ^a   Berthel, Steven J ^a   Bolin, David R ^a   Gillespie, Paul B ^a   Huby, Nicholas ^a   Olson, Gary L ^a   Sarabu, Ramakanth ^a   Guenot, Jeanmarie ^a   Madison, Vincent ^a   Hammer, Jürgen ^b   Sinigaglia, Francesco ^b   Steinmetz, Michael ^a,c   Nagy, Zoltan A ^a,c  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE MILANO RICERCHE   (Italy)

^c Genome Pharmaceuticals Corporation   (Germany)

Author keywords

Antigen presentation; Autoimmune disease; Peptidomimetics

Indexed keywords

HLA ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; BINDING SITE; HLA SYSTEM; IMMUNE RESPONSE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ARTHRITIS, RHEUMATOID; CATHEPSINS; CELL LINE; HLA-DR ANTIGENS; HUMANS; HYDROGEN BONDING; MOLECULAR MIMICRY; OLIGOPEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES;

EID: 0033052417     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/9865     Document Type: Article

References (40)

1. Nepom, B.S. The role of the major histocompatibility complex in autoimmunity. Clin. Immunol. Immunopathol. 67, S50-S55 (1993).
2. Schiff, B., Mizrachi, Y., Orgad, S., Yaron, M. & Gazit, I. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. Ann. Rheum. Dis. 41, 403-404 (1982).
3. McMichael, S.J., Sasazuki, T., McDevitt, H.O. & Payne, R.O. Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum. 20, 1037-1042 (1977).
4. Ohta, N. et al. Association between HLA and Japanese patients with rheumatoid arthritis. Hum. Immunol. 5, 123-132 (1982).
5. Nepom, G.T. et al. HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum. 32, 15-21 (1989).
6. Wordsworth, P. et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am. J. Hum. Genet. 51, 585-591 (1992).
7. Lanchbury, J.S. et al. Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum. Immunol. 32, 56-64 (1991).
8. Gregersen, P.K., Silver, J. & Winchester, R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213 (1987).
9. Brown, J.H. et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364, 33-39 (1993).
10. Stern, L.J. et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215-221 (1994).
11. Dessen, A., Lawrence, C.M., Cupo, S., Zaller, D.M. & Wiley, D.C. X-ray crystal structure of HLA-DR4 (DRA1*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7, 473-481 (1997).
12. Hammer, J. et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 181, 1847-1855 (1995).
13. Wucherpfennig, K.W. et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 92, 11935-11939 (1995).
14. Todd, J.A. et al. A molecular basis for MHC class II-associated autoimmunity. Science 240, 1003-1009 (1988).
15. Hammer, J., Takacs, B. & Sinigaglia, F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 176, 1007-1013 (1992).
16. Hammer, J. et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74, 197-203 (1993).
17. Adorini, L. et al. In vivo competition between self peptides and foreign antigens in T cell activation. Nature 334, 623-625 (1988).
18. Sakai, K. et al. Prevention of experimental encephalomyelitis with peptides that block the interaction of T cells with major histocompatibility complex proteins. Proc. Natl. Acad. Sci. USA 86, 9470-9474 (1989).
19. Hurtenbach, U., Lier, E., Adorini, L. & Nagy, Z.A. Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide. J. Exp. Med. 177, 1499-1504 (1993).
20. Ishioka, G.Y. et al. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides. J. Immunol. 152, 4310-4319 (1994).
21. Bennett, K. et al. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur. J. Immunol. 22, 1519-1524 (1992).
22. Weiss, G.A., Collins, E.J., Garboczi, D.N., Wiley, D.C., & Schreiber, S.L. A tricyclic ring system replaces the variable regions of peptides presented by three alleles of human MHC class I molecules. Chem. Biol. 2, 401-407 (1995).
23. Hammer, J. et al. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc. Natl. Acad. Sci. USA 91, 4456-4460 (1994).
24. Hammer, J. et al. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180, 2353-2358 (1994).
25. Ghosh, P., Amaya, M., Mellins, E. & Wiley, D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457-462 (1995).
26. Woulfe, S.L. et al. A peptidomimetic which specifically inhibits human leukocyte antigen DR4 Dw4-restricted T cell proliferation. J. Pharmacol. Exp. Ther. 281, 663-669 (1997).
27. Ito, K. et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183, 2635-2644 (1996).
28. Siklodi, B. et al. Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells. Hum. Immunol. 59, 463-471 (1998).
29. Barany, G. & Merrifield, R.B. in The peptides. Vol. 2 (eds Gross, E. & Meienhofer, J.) 1-284 (Academic, New York; 1980).
30. Stork, G., Leong, A.Y.W., & Touzin, A.M. Alkylation and Michael additions of glycine ethyl ester. J. Organic Chem. 41, 3491-3493 (1976).
31. Cho, J.-H. & Djerassi, C. Minor and trace from marine invertebrates. 58. Stereostructure and synthesis of new sponge sterols jaspisterol and isojaspisterol. J. Organic Chem. 52, 4517-4521 (1987).
32. Lapatsanis, L., Milias, G., Froussios, K., & Kolovos, M. Synthesis of N-(2,2,2-trichloroethoxycarbonyl) L-amino acids and N-(9-fluorenylmethoxycarbonyl) L-amino acids involving succinimidoxy anion as a leaving group in amino acid protection. Synthesis 8, 671-673 (1983).
33. Evans, D.A. & Ellman, J.A. The total syntheses of the isodityrosine-derived cyclic tripeptides OF4949-III and K-13. Determination of the absolute configuration of K-13. J. Am. Chem. Soc. 111, 1063-1072 (1989).
34. Dorrow, R.L. & Gingrich, D.E. A novel preparation of scalemic N-methyl-α-aminoacids. J. Organic Chem. 60, 4986-4987 (1995).
35. Chung, J.Y.L. et al. Conformationally constrained amino acids. Synthesis and optical resolution of 3-substituted proline derivatives. J. Org. Chem. 55, 270-275 (1990).
36. Attwood, M.R., Hassall, C.H., Krohn, A., Lawton, G., & Redhaw, S. The design and synthesis of the angiotensin converting enzyme inhibitor cliazapril and related bicyclic compounds. J. Chem. Soc. Perkin Trans. I, 1011-1019 (1986).
37. De Lombaert, S. et al. Practical syntheses of a novel tricyclic dipeptide mimetic based on a [6H]-azepinoindoline nucleus: application to angiotensin-converting enzyme inhibition. Tetrahedron Lett. 35, 7513-7516 (1994).
38. Gordon, T. et al. Peptide azoles: a new class of biologically-active dipeptide mimetics. Bioorg. Med. Chem. Lett. 3, 915-920. (1993).
39. Falcioni, F. et al. Influence of CD26 and integrins on the antigen sensitivity of human memory T cells. Hum. Immunol. 50, 79-90 (1996).
40. Sinigaglia, F. et al. A malaria T-cell epitope recognized with most mouse and human MHC class II molecules. Nature 336, 778-780 (1988).